
3TMPO
NCT04000776
JCP093
Triple-tracer Molecular Imaging Using 18F-FDG, 68Ga-PSMA and 68Ga-OCTREOTATE to Characterize Metastatic Castration-resistant Prostate Cancer (mCRPC) and Evaluate Eligibility for Radionuclide Therapies
Status:
Opening Soon

Observational
Phase

N/A
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
N/A
Investigational
Product
n/a
Treatment Arms
o Diagnostic Test: FDG Positron emission tomography (PET) scan
o Diagnostic Test: PSMA Positron emission tomography (PET) scan
o Diagnostic Test: OCTREOTATE Positron emission tomography (PET) scan
o Other: Optional Bone or soft-tissue biopsies